• Aptevo Therapeutics secured agreements for cash exercises of existing common warrants, generating expected gross proceeds of approximately $3 million.
• Holders will exercise warrants covering 2,777,778 common shares at a reduced exercise price of $1.08 per share.
• In exchange, holders will receive new unregistered common stock purchase warrants covering 13,888,890 shares at an exercise price of $1.08 per share.
• The new warrants become exercisable upon required stockholder approval, expiring five years after their initial exercise date.
• The transaction is expected to close around November 12, 2026, subject to customary conditions; net proceeds will fund working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611110900ACCESSWRNAPR_____1249823) on November 11, 2026, and is solely responsible for the information contained therein.